Drawing for ANVO

USPTO serial 88019481

ANVO

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
MILLER, JUSTIN T
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ANVO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jeffrey M. Furr

Jeffrey M. Furr Furr Law Firm2622 Debolt RoadUtica, OH 43080UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, namely anticoagulants, for skin care, for treating diabetes; veterinary preparations, namely antioxidants, pain relief medication, for treatment of intestinal bacteria, for treatment of parasites and worms; Sanitary preparations for medical use; pharmaceutical preparations, namely, chemical preparations and substances, gels, creams, lotions, ointments, sprays, powders, and other products for the treatment of dermatological conditions and disorders and other infections of the human skin; personal hygiene products, namely, feminine hygiene pads and tampons, douching preparations for medical use, medicated pre-moistened towelettes and tissues; menstrual system treatment preparations; pharmaceutical preparations in the field of women's health, namely, contraceptives, hormone replacement therapies and pharmaceuticals for treating menopause and its symptoms; dietetic substances for medical use, namely, diet capsules and pills; antiseptics; baby food; materials for tooth fillings and for dental impressions; medical and hygienic disinfectants; bactericides for treating or preventing infections; medical adhesive and menstruation bandages, surgical bandages, adhesive bandages, gauze bandages, bandages for skin wounds; antibiotic ointments, hemorrhoidal ointments, vaginal ointments; calamine lotion; pharmaceutical preparations for treating and preventing insect bites; Dietary and nutritional supplements; Gummy vitamins; Herbal supplements; Liquid vitamin supplements; Medicinal herbal preparations; Mixed vitamin preparations; Multi-vitamin preparations; Natural herbal supplements; Prenatal vitamins; Vitamin A preparations; Vitamin and mineral supplements; Vitamin B preparations; Vitamin C preparations; Vitamin D preparations; multivitamin preparations; Medicated dental rinses; cough syrups; enema preparations; natural health products in the nature of natural dietary supplements, nutritional supplements and homeopathic supplements, containing vitamins, minerals, green foods, antioxidants, herbal extracts, fruit concentrates, proteins, amino acids, plant oils and fiber in powder, capsule, tablet and liquid form; Medicinal and pharmaceutical preparations, namely, analgesics, diuretics, carbonic anhydrase inhibitors in the nature of pharmaceutical preparations used to treat glaucoma, antidepressants, antibiotics, anti-anginal agents, antihypertensives, antiparkinsonian agents in the nature of pharmaceutical agents for treating Parkinson's disease, laxatives, vitamin supplements, calcium supplements, anticonvulsants, anticholinergics, anxiolytics, antianxiety agents, hypoglycemic agents, anti-hystaminics, sedatives, platelet inhibitors, vasodilators; antipsychotics, hypnotics, pharmaceutical preparations used to treat anemia, anti-inflammatory agents, antiemetics, potassium supplements, trichomonacides in the nature of pharmaceutical preparations used to treat trichomoniasis; bronchodilators, urinary antibacterial pharmaceuticals, antiarthritic preparations, glucocorticoids, antiarrhythmic agents, uricosurics, glaucoma therapy preparations, antispasmodic preparations, antihistamines, anti-inflammatories, antifungal preparations and creams for medical use, neuroleptics, pharmaceutical agents used to treat tuberculosis; psychotherapeutics, namely, tranquillizers; antiparkinsonians in the nature of pharmaceutical preparations used to treat Parkinson's disease; antidiabetics preparations; antibacterial pharmaceuticals, spray, cleaners and soap; antiarthritic compositions and preparations; antiarrhythmics; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; all of the above expressly excluding pesticidesACTIVE—
035Promoting the pharmaceutical products of others by advertising and marketing; Marketing services relating to pharmaceutical products and devices, namely, providing pharmacists and other healthcare professionals with marketing information, advice and guidance, access to healthcare specialists, information kiosks, printed and electronic materials, all for use to enhance professional image, building pharmacy and healthcare practices and promoting excellence in pharmacy; Business management of pharmaceutical products related reimbursement programs for others; management of business affairs; commercial administration of the licensing of the goods and services of others; public relations; assistance and consulting relating to marketing and corporate communication; providing office functions; quality management services in the nature of business management services for establishing business quality policy and determining business means for implementing those policies to improve customer satisfaction; business development services; sales promotion servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Nov 30, 2020MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 30, 2020ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 28, 2020NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 3, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 3, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 12, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 27, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 3, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 3, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 3, 2020ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Jan 3, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 3, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 2, 2020WOAGWITHDRAWAL OF ATTORNEY GRANTED—
Jan 2, 2020WOARTEAS WITHDRAWAL OF ATTORNEY RECEIVED—
Jan 2, 2020GNS1NOTIFICATION OF SUBSEQUENT FINAL EMAILED—
Jan 2, 2020GNCFCONTINUATION OF FINAL REFUSAL E-MAILED—
Jan 2, 2020CNCFACTION CONTINUING A FINAL - COMPLETED—
Dec 4, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 3, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 3, 2019ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Dec 3, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 3, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 4, 2019GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jun 4, 2019GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jun 4, 2019CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 9, 2019AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
May 9, 2019PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Apr 26, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 25, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 25, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 25, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 25, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 25, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 18, 2018DOCKASSIGNED TO EXAMINER—
Jul 5, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 2, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance